SEC Form 4 research
| Issuer | Pyxis Oncology, Inc. |
|---|---|
| Tickers | PYXS, PYXO |
| Reporting owners | 29 |
| Officers and directors | 7 |
| Last public filing | 2026-10-09 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-10-09 | 2026-10-01 | Gordon Craig D, GordonMD Global Investments LP, GordonMD Long Biased GP LLC, GordonMD Long Biased Master Fund LP | P | 7,172,000 | Not reported | Not reported |
| 2026-10-02 | 2026-10-01 | Gordon Craig D, GordonMD Global Investments LP, GordonMD Long Biased GP LLC, GordonMD Long Biased Master Fund LP | P | 5,517,000 | Not reported | Not reported |
| 2026-10-02 | 2026-10-01 | Gordon Craig D, GordonMD Global Investments LP, GordonMD Long Biased GP LLC, GordonMD Long Biased Master Fund LP | P | 7,546,766 | Not reported | Not reported |
| 2026-09-08 | 2026-09-04 | Civik Thomas | A | 2,503,050 | $0 | Not reported |
| 2026-08-20 | 2026-08-20 | Dupont Jakob | A | 46,000 | $0 | Not reported |
| 2026-08-14 | 2026-08-12 | Civik Thomas | A | 250,956 | $0 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.